ClinicalTrials.gg
CompletedNCT01517412Updated Oct 14, 2016Results posted

Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin

A Phase 3 interventional study of Lixisenatide (AVE0010) and Self-injector pen device (OptiClik®) in Type 2 Diabetes Mellitus, sponsored by Sanofi. Completed at 82 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-10-14.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
451
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 47 studies testing lixisenatide in Diabetes Mellitus, Type 2 — 1 open to participants now, 2 under way, none of them phase 3. lixisenatide · Diabetes Mellitus, Type 2.

Enrollment
16th of 47
451 · median 321
Started
2012
with 3 others
Phase 3
29 of 47
none open now
Registered
16th of 47
by date
Lead sponsor
38 of 47
Sanofi

Among the 47 studies testing lixisenatide in Diabetes Mellitus, Type 2, this one is the 16th largest by enrollment, is one of 4 that started in 2012, is one of 29 in phase 3, and was the 16th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 47 studies testing lixisenatide in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About lixisenatide

lixisenatide: first FDA approval 2016 (ADLYXIN), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies testing lixisenatide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Primary Objective:

  • To compare the two treatment regimens in terms of change of glycosylated hemoglobin (HbA1c) from baseline to endpoint (Week 24)

Secondary Objective:

  • To assess the effect of the 2 lixisenatide regimens on:

    • The percentage of participants who reached the target of HbA1c \< 7% or ≤ 6.5% at Week 24
    • Fasting Plasma Glucose (FPG)
    • 7-point Self-Monitored Plasma Glucose (SMPG) profiles
    • Body weight
  • To assess the safety and tolerability of the 2 lixisenatide regimens
Read the detailed description

The maximum study duration was 28 weeks per participant, including a 24-week randomized treatment period.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with type 2 diabetes mellitus, diagnosed for at least 1 year before screening visit
  • Metformin treatment at a stable dose of at least 1.5 g/day for at least 3 months prior to screening visit.

Exclusion criteria

Exclusion criteria:

  • Screening \< 7.0% and > 10.0%
  • Fasting plasma glucose at screening > 250 mg/dL (> 13.9 mmol/L)
  • Treatment with glucose-lowering agent(s) other than metformin in a period of 3 months prior to screening, previous use of insulin
  • Participants who usually did not eat breakfast
  • Type 1 diabetes mellitus
  • (BMI) ≤ 20 kg/m\^2 and > 40 kg/m\^2
  • Pregnancy or lactation, women of with no effective method
  • Amylase and/or lipase > 3 times the laboratory range ( ULN) at screening
  • (ALT) > 3 ULN at screening
  • Calcitonin ≧ 20 pg/ml (5.9 pmol/L) at screening
  • History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy.
  • Personal or immediate family history of medullary thyroid cancer (MTC) or genetic conditions that predisposes to MTC (e.g. multiple endocrine neoplasia syndromes)
  • Any related to metformin
  • Any previous treatment with lixisenatide

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
451 participants (actual)

Study arms

  • Experimental
    Lixisenatide Main Meal

    Lixisenatide 10 mcg once daily (QD) within 1 hour before "main meal of the day" for 2 weeks, then at a maintenance dose of 20 mcg QD up to Week 24.

    Drug: Lixisenatide (AVE0010) · Device: Self-injector pen device (OptiClik®) · Drug: Metformin

  • Active comparator
    Lixisenatide Breakfast

    Lixisenatide 10 mcg QD within 1 hour before "breakfast" for 2 weeks, then at a maintenance dose of 20 mcg QD up to Week 24.

    Drug: Lixisenatide (AVE0010) · Device: Self-injector pen device (OptiClik®) · Drug: Metformin

Interventions

  • Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous

  • DeviceSelf-injector pen device (OptiClik®)
  • To be kept at stable dose (≥1.5 g/day) throughout the study.

    Also known as: Route of administration: Oral

06

What researchers measure

Primary outcomes

  1. Change in HbA1c From Baseline to Week 24

    Change in HbA1C was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using last observation carried forward (LOCF). On-treatment period for this efficacy variable was defined as the time from the first dose of study drug up to 14 days after the last dose of study drug. Here, number of participants analyzed = participants with baseline and at least one post-baseline HbA1c assessment during on-treatment period.

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Percentage of Participants With HbA1c Level <7 % or ≤6.5% at Week 24

    Here, number of participants analyzed = participants with baseline and at least one post-baseline HbA1c assessment during on-treatment period.

    Time frame: Week 24

  2. Change in Average 7-point SMPG Profiles From Baseline to Week 24

    Participants recorded a 7-point plasma glucose profile measured before and 2 hours after each meal and at bedtime two times in a week before baseline, before visit Week 8, before visit Week 12 and before visit week 24. The average value across the profiles performed in the week a visit for the 7-time points was calculated. Change in average 7-point SMPG was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using LOCF. The on-treatment period for this efficacy variable was defined as the time from the first dose of study drug up to the day of last dose of study drug. Here, number of participants analyzed = participants with baseline and at least one post-baseline 7-point SMPG assessment during on-treatment period.

    Time frame: Baseline, Week 24

  3. Change in FPG From Baseline to Week 24

    Change in FPG was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using LOCF. The on-treatment period for this efficacy variable was the time from the first dose of study drug up to 1 day after the last dose of study drug. Here, number of participants analyzed = participants with baseline and at least one post-baseline FPG assessment during on-treatment period.

    Time frame: Baseline, Week 24

  4. Change in Body Weight From Baseline to Week 24

    Change in body weight was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using LOCF. On-treatment period for this efficacy variable was defined as the time from the first dose of study drug up to 3 days after the last dose of study drug. Here, number of participants analyzed = participants with baseline and at least one post-baseline body weight assessment during on-treatment period.

    Time frame: Baseline, Week 24

  5. Percentage of Participants Who Reached the Target of HbA1c <7% at Week 24 And Did Not Experience Confirmed Symptomatic Hypoglycemia (Plasma Glucose [PG] <60 mg/dL [3.3 mmol/L]) During 24-Week Treatment Period

    Symptomatic hypoglycemia was defined as an event with clinical symptoms that were considered to result from hypoglycemic episode with an accompanying PG\<60 mg/dL (3.3 mmol/L) or associated with prompt recovery after oral carbohydrate if no PG measurement was available. On-treatment period for symptomatic hypoglycemia assessment was defined as time from first dose of study drug up to 1 day after last dose of study drug. Participants without any post-baseline on-treatment value for HbA1c were counted as non-responders if they experienced at least one symptomatic hypoglycemia. Otherwise, they were counted as missing.

    Time frame: Week 24

  6. Percentage of Participants Who Reached the Target of HbA1c <7% And Had No Body Weight Gain at Week 24

    Participants without post-baseline on-treatment values for (HbA1c and body weight) that were no more than 30 days apart were counted as non-responders if at least one of the components (HbA1c and/or body weight) was available and showed no response. Otherwise, they were counted as missing.

    Time frame: Week 24

  7. Percentage of Participants Who Reached the Target of HbA1c <7% And Had No Body Weight Gain at Week 24 And Did Not Experience Confirmed Symptomatic Hypoglycemia (PG<60 mg/dL [3.3 mmol/L]) During the 24-Week Treatment Period

    Participants without post-baseline on-treatment values (for HbA1c and body weight) that were no more than 30 days apart not more than 30-days apart were counted as non-responders if at least one of components (HbA1c and/or body weight) was available and showed no response. Otherwise, they were counted as missing.

    Time frame: Week 24

  8. Percentage of Participants Who Reached the Target of HbA1c <7% And Had a 2-hour Postprandial Plasma Glucose (PPG) <140mg/dL After Breakfast or Main Meal At Week 24

    On-treatment period for 2-hour PPG assessment was defined as the time from the first dose of study drug up to the day of last dose of study drug. Participants without post-baseline on-treatment values (for HbA1c and 2-hour PPG) that were no more than 30-days apart were counted as non-responders if at least one of the components (HbA1cand/or 2-hour PPG) was available and showed no response. Otherwise, they were counted as missing.

    Time frame: Week 24

  9. Change in Diabetes Treatment Satisfaction Questionnaire Score (DTSQs) From Baseline to Week 24

    DTSQ is a validated measure to assess how satisfied participants with diabetes are with their treatment and how they perceive hyper- and hypoglycemia. It consists of 8 questions which are answered on a Likert scale from 0 to 6. DTSQ treatment satisfaction score is the sum of question 1, 4, 5, 6, 7 and 8 scores and ranges between 0 and 36, where higher scores indicate more treatment satisfaction. On-treatment period for treatment satisfaction assessment was defined as the time from the first dose of study drug up to 3 days after the last dose of study drug. Missing data was imputed using LOCF. Here, number of participants analyzed = participants with both baseline and Week 24 DTSQ score assessment during on-treatment period.

    Time frame: Baseline, Week 24

07

Results

Posted Oct 14, 2016

Participant flow

The study was conducted at 82 centers in 10 countries. A total of 734 participants were screened between February 15, 2012 and October 16, 2012. 283 participants were screen failures; main reason for screen failure was that glycosylated hemoglobin (HbA1c) values were out of protocol defined range. 451 participants were randomized.

Participant flow — Overall Study
MilestoneLixisenatide Main MealLixisenatide Breakfast
Started225226
Completed189202
Not completed3624
Withdrew: Adverse event1011
Withdrew: Lack of efficacy105
Withdrew: Poor compliance to protocol83
Withdrew: Other than specified above85

Outcome measures

PrimaryChange in HbA1c From Baseline to Week 24

Change in HbA1C was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using last observation carried forward (LOCF). On-treatment period for this efficacy variable was defined as the time from the first dose of study drug up to 14 days after the last dose of study drug. Here, number of participants analyzed = participants with baseline and at least one post-baseline HbA1c assessment during on-treatment period.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Percentage of hemoglobin
Change in HbA1c From Baseline to Week 24
Percentage of hemoglobinLixisenatide Main MealLixisenatide Breakfast
Change in HbA1c From Baseline to Week 24-0.65 ± 0.074-0.74 ± 0.074
Statistical analysis
  • Lixisenatide Main Meal vs Lixisenatide Breakfast · Least square (ls) mean difference: 0.09 · 95% CI -0.067 to 0.242Lixisenatide Main Meal vs Lixisenatide Breakfast
  • Lixisenatide Main Meal vs Lixisenatide Breakfast · ANCOVA · p = 0.2664 (Threshold for significance at 0.05 level.) · Ls mean difference: 0.09Lixisenatide Main Meal vs Lixisenatide Breakfast
SecondaryPercentage of Participants With HbA1c Level <7 % or ≤6.5% at Week 24

Here, number of participants analyzed = participants with baseline and at least one post-baseline HbA1c assessment during on-treatment period.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With HbA1c Level <7 % or ≤6.5% at Week 24
Percentage of participantsLixisenatide Main MealLixisenatide Breakfast
HbA1c <7%43.642.8
HbA1c ≤6.5%22.525.7
SecondaryChange in Average 7-point SMPG Profiles From Baseline to Week 24

Participants recorded a 7-point plasma glucose profile measured before and 2 hours after each meal and at bedtime two times in a week before baseline, before visit Week 8, before visit Week 12 and before visit week 24. The average value across the profiles performed in the week a visit for the 7-time points was calculated. Change in average 7-point SMPG was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using LOCF. The on-treatment period for this efficacy variable was defined as the time from the first dose of study drug up to the day of last dose of study drug. Here, number of participants analyzed = participants with baseline and at least one post-baseline 7-point SMPG assessment during on-treatment period.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · mmol/L
Change in Average 7-point SMPG Profiles From Baseline to Week 24
mmol/LLixisenatide Main MealLixisenatide Breakfast
Change in Average 7-point SMPG Profiles From Baseline to Week 24-0.80 ± 0.145-1.10 ± 0.145
SecondaryChange in FPG From Baseline to Week 24

Change in FPG was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using LOCF. The on-treatment period for this efficacy variable was the time from the first dose of study drug up to 1 day after the last dose of study drug. Here, number of participants analyzed = participants with baseline and at least one post-baseline FPG assessment during on-treatment period.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · mmol/L
Change in FPG From Baseline to Week 24
mmol/LLixisenatide Main MealLixisenatide Breakfast
Change in FPG From Baseline to Week 24-0.35 ± 0.192-0.57 ± 0.193
SecondaryChange in Body Weight From Baseline to Week 24

Change in body weight was calculated by subtracting baseline value from Week 24 value. Missing data was imputed using LOCF. On-treatment period for this efficacy variable was defined as the time from the first dose of study drug up to 3 days after the last dose of study drug. Here, number of participants analyzed = participants with baseline and at least one post-baseline body weight assessment during on-treatment period.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · kg
Change in Body Weight From Baseline to Week 24
kgLixisenatide Main MealLixisenatide Breakfast
Change in Body Weight From Baseline to Week 24-2.60 ± 0.320-2.80 ± 0.319
SecondaryPercentage of Participants Who Reached the Target of HbA1c <7% at Week 24 And Did Not Experience Confirmed Symptomatic Hypoglycemia (Plasma Glucose [PG] <60 mg/dL [3.3 mmol/L]) During 24-Week Treatment Period

Symptomatic hypoglycemia was defined as an event with clinical symptoms that were considered to result from hypoglycemic episode with an accompanying PG\<60 mg/dL (3.3 mmol/L) or associated with prompt recovery after oral carbohydrate if no PG measurement was available. On-treatment period for symptomatic hypoglycemia assessment was defined as time from first dose of study drug up to 1 day after last dose of study drug. Participants without any post-baseline on-treatment value for HbA1c were counted as non-responders if they experienced at least one symptomatic hypoglycemia. Otherwise, they were counted as missing.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Who Reached the Target of HbA1c <7% at Week 24 And Did Not Experience Confirmed Symptomatic Hypoglycemia (Plasma Glucose [PG] <60 mg/dL [3.3 mmol/L]) During 24-Week Treatment Period
Percentage of participantsLixisenatide Main MealLixisenatide Breakfast
Percentage of Participants Who Reached the Target of HbA1c <7% at Week 24 And Did Not Experience Confirmed Symptomatic Hypoglycemia (Plasma Glucose [PG] <60 mg/dL [3.3 mmol/L]) During 24-Week Treatment Period40.441.0
SecondaryPercentage of Participants Who Reached the Target of HbA1c <7% And Had No Body Weight Gain at Week 24

Participants without post-baseline on-treatment values for (HbA1c and body weight) that were no more than 30 days apart were counted as non-responders if at least one of the components (HbA1c and/or body weight) was available and showed no response. Otherwise, they were counted as missing.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Who Reached the Target of HbA1c <7% And Had No Body Weight Gain at Week 24
Percentage of participantsLixisenatide Main MealLixisenatide Breakfast
Percentage of Participants Who Reached the Target of HbA1c <7% And Had No Body Weight Gain at Week 2440.838.6
SecondaryPercentage of Participants Who Reached the Target of HbA1c <7% And Had No Body Weight Gain at Week 24 And Did Not Experience Confirmed Symptomatic Hypoglycemia (PG<60 mg/dL [3.3 mmol/L]) During the 24-Week Treatment Period

Participants without post-baseline on-treatment values (for HbA1c and body weight) that were no more than 30 days apart not more than 30-days apart were counted as non-responders if at least one of components (HbA1c and/or body weight) was available and showed no response. Otherwise, they were counted as missing.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Who Reached the Target of HbA1c <7% And Had No Body Weight Gain at Week 24 And Did Not Experience Confirmed Symptomatic Hypoglycemia (PG<60 mg/dL [3.3 mmol/L]) During the 24-Week Treatment Period
Percentage of participantsLixisenatide Main MealLixisenatide Breakfast
Percentage of Participants Who Reached the Target of HbA1c <7% And Had No Body Weight Gain at Week 24 And Did Not Experience Confirmed Symptomatic Hypoglycemia (PG<60 mg/dL [3.3 mmol/L]) During the 24-Week Treatment Period38.137.2
SecondaryPercentage of Participants Who Reached the Target of HbA1c <7% And Had a 2-hour Postprandial Plasma Glucose (PPG) <140mg/dL After Breakfast or Main Meal At Week 24

On-treatment period for 2-hour PPG assessment was defined as the time from the first dose of study drug up to the day of last dose of study drug. Participants without post-baseline on-treatment values (for HbA1c and 2-hour PPG) that were no more than 30-days apart were counted as non-responders if at least one of the components (HbA1cand/or 2-hour PPG) was available and showed no response. Otherwise, they were counted as missing.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Who Reached the Target of HbA1c <7% And Had a 2-hour Postprandial Plasma Glucose (PPG) <140mg/dL After Breakfast or Main Meal At Week 24
Percentage of participantsLixisenatide Main MealLixisenatide Breakfast
Percentage of Participants Who Reached the Target of HbA1c <7% And Had a 2-hour Postprandial Plasma Glucose (PPG) <140mg/dL After Breakfast or Main Meal At Week 2428.927.6
SecondaryChange in Diabetes Treatment Satisfaction Questionnaire Score (DTSQs) From Baseline to Week 24

DTSQ is a validated measure to assess how satisfied participants with diabetes are with their treatment and how they perceive hyper- and hypoglycemia. It consists of 8 questions which are answered on a Likert scale from 0 to 6. DTSQ treatment satisfaction score is the sum of question 1, 4, 5, 6, 7 and 8 scores and ranges between 0 and 36, where higher scores indicate more treatment satisfaction. On-treatment period for treatment satisfaction assessment was defined as the time from the first dose of study drug up to 3 days after the last dose of study drug. Missing data was imputed using LOCF. Here, number of participants analyzed = participants with both baseline and Week 24 DTSQ score assessment during on-treatment period.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Units on a scale
Change in Diabetes Treatment Satisfaction Questionnaire Score (DTSQs) From Baseline to Week 24
Units on a scaleLixisenatide Main MealLixisenatide Breakfast
Change in Diabetes Treatment Satisfaction Questionnaire Score (DTSQs) From Baseline to Week 243.01 ± 0.5463.54 ± 0.529

Adverse events

Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Day 171) regardless of seriousness or relationship to investigational medicinal product (IMP).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lixisenatide Main Meal—7/225 (3.1%)65/225 (28.9%)
Lixisenatide Breakfast—7/226 (3.1%)60/226 (26.5%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventLixisenatide Main MealLixisenatide Breakfast
Renal colicRenal and urinary disorders2/2250/226
CellulitisInfections and infestations1/2250/226
Clear cell renal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2250/226
Myocardial infarctionCardiac disorders1/2250/226
Peripheral arterial occlusive diseaseVascular disorders1/2250/226
Cystitis noninfectiveRenal and urinary disorders1/2250/226
Postoperative wound infectionInfections and infestations0/2251/226
Cerebral infarctionNervous system disorders0/2251/226
Atrial fibrillationCardiac disorders0/2251/226
Abdominal herniaGastrointestinal disorders0/2251/226
Most frequent other events
Most frequent other events
EventLixisenatide Main MealLixisenatide Breakfast
NauseaGastrointestinal disorders33/22535/226
NasopharyngitisInfections and infestations22/22516/226
HeadacheNervous system disorders8/22516/226
HypoglycaemiaMetabolism and nutrition disorders15/2257/226

Baseline characteristics

Age, Continuous
Age, Continuous(years)Lixisenatide Main MealLixisenatide BreakfastTotal
Mean56.3 ± 10.657.5 ± 9.756.9 ± 10.2
Sex: Female, Male
Sex: Female, Male(Participants)Lixisenatide Main MealLixisenatide BreakfastTotal
Female124129253
Male10197198
Race
Race(participants)Lixisenatide Main MealLixisenatide BreakfastTotal
Caucasian/White211211422
Black4812
Asian/Oriental10717
Ethnicity
Ethnicity(participants)Lixisenatide Main MealLixisenatide BreakfastTotal
Hispanic111223
Non-Hispanic214214428
Number of Participants with Categorical Body Mass Index (BMI)
Number of Participants with Categorical Body Mass Index (BMI)(participants)Lixisenatide Main MealLixisenatide BreakfastTotal
<30 kg/m^25160111
≥30 kg/m^2174166340
BMI, Continuous
BMI, Continuous(kg/m^2)Lixisenatide Main MealLixisenatide BreakfastTotal
Mean33.47 ± 4.5032.77 ± 4.6233.12 ± 4.57
HbA1c
HbA1c(Percentage of hemoglobin)Lixisenatide Main MealLixisenatide BreakfastTotal
Mean7.85 ± 0.767.93 ± 0.787.89 ± 0.77
Fasting Plasma Glucose (FPG)
Fasting Plasma Glucose (FPG)(mmol/L)Lixisenatide Main MealLixisenatide BreakfastTotal
Mean9.22 ± 2.039.31 ± 2.049.26 ± 2.03

4 further baseline measures are reported on the registry.

08

Study locations

82 sites
  • Investigational Site Number 840112
    Glendale, Arizona 85306, United States
  • Investigational Site Number 840113
    Mesa, Arizona 85213, United States
  • Investigational Site Number 840105
    Phoenix, Arizona 85028, United States
  • Investigational Site Number 840102
    Tempe, Arizona 85282, United States
  • Investigational Site Number 840107
    Tempe, Arizona, United States
  • Investigational Site Number 840116
    Mission Viejo, California 92691, United States
  • Investigational Site Number 840103
    Northridge, California 91325, United States
  • Investigational Site Number 840118
    Redlands, California 92374, United States
  • Investigational Site Number 840104
    Temecula, California 92591, United States
  • Investigational Site Number 840122
    Chicago, Illinois 60611, United States
  • Investigational Site Number 840119
    Chicago, Illinois 60616, United States
  • Investigational Site Number 840114
    Springfield, Illinois 62704, United States
  • Investigational Site Number 840120
    Flint, Michigan 48504, United States
  • Investigational Site Number 840115
    Billings, Montana 59103, United States
  • Investigational Site Number 840101
    Sea Girt, New Jersey 08750, United States
  • Investigational Site Number 840111
    Fargo, North Dakota 58103, United States
  • Investigational Site Number 840110
    West Jordan, Utah 84088, United States
  • Investigational Site Number 124102
    Brampton, L6R 3J5, Canada
  • Investigational Site Number 124108
    Coquitlam, V3K 3P4, Canada
  • Investigational Site Number 124106
    Etobicoke, M9R 4E1, Canada
  • Investigational Site Number 124113
    Kelowna, V1Y 1Z9, Canada
  • Investigational Site Number 124110
    Laval, H7T 2P5, Canada
  • Investigational Site Number 124103
    Newmarket, L3Y 5G8, Canada
  • Investigational Site Number 124101
    Oakville, L6H 3P1, Canada
  • Investigational Site Number 124111
    St-Romuald, G6W 5M6, Canada
  • Investigational Site Number 124104
    Thornhill, L4J 8L7, Canada
  • Investigational Site Number 124105
    Toronto, M9V 4B4, Canada
  • Investigational Site Number 124112
    Vancouver, V5Z 1M9, Canada
  • Investigational Site Number 203104
    Plzen, 32600, Czech Republic
  • Investigational Site Number 203102
    Praha 10, 10000, Czech Republic
  • Investigational Site Number 203101
    Praha 10, 10034, Czech Republic
  • Investigational Site Number 203105
    Praha 2, 12808, Czech Republic
  • Investigational Site Number 203103
    Trutnov, 54101, Czech Republic
  • Investigational Site Number 203106
    Ujezd U Brna, 664 53, Czech Republic
  • Investigational Site Number 250108
    Clermont Ferrand, 63000, France
  • Investigational Site Number 250102
    Menton, 06500, France
  • Investigational Site Number 250103
    Nanterre, 92014, France
  • Investigational Site Number 250105
    Rennes, 35700, France
  • Investigational Site Number 276103
    Asslar, 35614, Germany
  • Investigational Site Number 276102
    Bad Mergentheim, 97980, Germany
  • Investigational Site Number 276107
    Berlin, 13125, Germany
  • Investigational Site Number 276101
    Heidelberg, 69115, Germany
  • Investigational Site Number 276104
    Künzing, 94550, Germany
  • Investigational Site Number 276105
    Pirna, 01796, Germany
  • Investigational Site Number 276108
    St. Ingbert-Oberwürzbach, 66386, Germany
  • Investigational Site Number 616106
    Bytom, 41-902, Poland
  • Investigational Site Number 616102
    Gdansk, 80-858, Poland
  • Investigational Site Number 616101
    Krakow, 31-450, Poland
  • Investigational Site Number 616103
    Lublin, 20-538, Poland
  • Investigational Site Number 616108
    Oswiecim, 32-600, Poland
  • Investigational Site Number 616105
    Wroclaw, 50-127, Poland
  • Investigational Site Number 616104
    Wroclaw, 50-306, Poland
  • Investigational Site Number 616107
    Wroclaw, 50-403, Poland
  • Investigational Site Number 642101
    Bucuresti, 050538, Romania
  • Investigational Site Number 642105
    Oradea, 410169, Romania
  • Investigational Site Number 642102
    Ploiesti, 100097, Romania
  • Investigational Site Number 642104
    Resita, 320076, Romania
  • Investigational Site Number 642103
    Timisoara, 300456, Romania
  • Investigational Site Number 643103
    Moscow, 119435, Russian Federation
  • Investigational Site Number 643101
    Moscow, 125367, Russian Federation
  • Investigational Site Number 643106
    Nizhny Novgorod, 603018, Russian Federation
  • Investigational Site Number 643102
    Samara, 443067, Russian Federation
  • Investigational Site Number 643107
    St-Petersburg, 194291, Russian Federation
  • Investigational Site Number 643105
    St-Petersburg, 194354, Russian Federation
  • Investigational Site Number 643110
    St-Petersburg, 195257, Russian Federation
  • Investigational Site Number 643108
    Vladimir, 600023, Russian Federation
  • Investigational Site Number 643104
    Voronezh, 394018, Russian Federation
  • Investigational Site Number 724104
    Barcelona, 08020, Spain
  • Investigational Site Number 724103
    Barcelona, 08041, Spain
  • Investigational Site Number 724102
    El Ferrol, 15403, Spain
  • Investigational Site Number 724101
    Hostalets De Balenyà, 08550, Spain
  • Investigational Site Number 724107
    La Coruña, 15006, Spain
  • Investigational Site Number 724106
    Málaga, 29010, Spain
  • Investigational Site Number 724108
    Segovia, 40002, Spain
  • Investigational Site Number 724105
    Sevilla, 41014, Spain
  • Investigational Site Number 804108
    Kharkiv, 61002, Ukraine
  • Investigational Site Number 804105
    Kharkov, 61022, Ukraine
  • Investigational Site Number 804102
    Kiev, 2091, Ukraine
  • Investigational Site Number 804103
    Kyiv, 04114, Ukraine
  • Investigational Site Number 804104
    Mykolaiv, 54003, Ukraine
  • Investigational Site Number 804106
    Poltava, 36011, Ukraine
  • Investigational Site Number 804101
    Zaporozhie, 69600, Ukraine
09

References and documents

Publications

  • Ahren B, Vorokhobina N, Souhami E, Demil N, Ye J, Aronson R. Equal improvement in glycaemia with lixisenatide given before breakfast or the main meal of the day. J Diabetes Complications. 2014 Sep-Oct;28(5):735-41. doi: 10.1016/j.jdiacomp.2014.05.012. Epub 2014 Jun 5. PubMed 25012990 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2012, a primary completion of May 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2016, 3 years 5 months after primary completion. A results delay was requested in May 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2012
First posted
Jan 25, 2012
Start
Feb 2012
Primary completionActual
May 2013
CompletionActual
May 2013
Results delay requested
May 6, 2014
Results first posted
Oct 14, 2016
Last update
Oct 14, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 14, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01517412
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jan 25, 2012
Start date
Feb 2012
Primary completion
May 2013
Completion
May 2013
Results posted
Oct 14, 2016
Last update
Oct 14, 2016

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lixisenatide · Metformin

Start the discussion